A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs. - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue Nature Communications Année : 2016

A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs.

Margus Varjak

Résumé

Chikungunya virus (CHIKV) is a globally spreading alphavirus against which there is no commercially available vaccine or therapy. Here we use a genome-wide siRNA screen to identify 156 proviral and 41 antiviral host factors affecting CHIKV replication. We analyse the cellular pathways in which human proviral genes are involved and identify druggable targets. Twenty-one small-molecule inhibitors, some of which are FDA approved, targeting six proviral factors or pathways, have high antiviral activity in vitro, with low toxicity. Three identified inhibitors have prophylactic antiviral effects in mouse models of chikungunya infection. Two of them, the calmodulin inhibitor pimozide and the fatty acid synthesis inhibitor TOFA, have a therapeutic effect in vivo when combined. These results demonstrate the value of loss-of-function screening and pathway analysis for the rational identification of small molecules with therapeutic potential and pave the way for the development of new, host-directed, antiviral agents.
Fichier principal
Vignette du fichier
ncomms11320.pdf (2.42 Mo) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

pasteur-01515939 , version 1 (28-04-2017)

Licence

Paternité

Identifiants

Citer

Alexander Karlas, Stefano Berre, Thérèse Couderc, Margus Varjak, Peter Braun, et al.. A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs.. Nature Communications, 2016, 7, pp.11320. ⟨10.1038/ncomms11320⟩. ⟨pasteur-01515939⟩
464 Consultations
449 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More